Boston Scientific (NYSE:BSX) Given New $45.00 Price Target at Barclays

Boston Scientific (NYSE:BSX) had its price objective dropped by investment analysts at Barclays from $48.00 to $45.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “equal weight” rating on the medical equipment provider’s stock. Barclays‘s price objective suggests a potential upside of 4.54% from the stock’s current price.

A number of other research firms have also recently issued reports on BSX. Truist Financial cut their target price on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Oppenheimer downgraded shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research report on Thursday. Piper Sandler lowered their target price on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, July 29th. JPMorgan Chase & Co. lowered Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price target on the stock. in a research report on Wednesday. Finally, Canaccord Genuity Group dropped their price objective on Boston Scientific from $66.00 to $48.00 and set a “buy” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Stock Up 0.8%

Shares of BSX traded up $0.36 during midday trading on Friday, reaching $43.05. 2,504,092 shares of the stock were exchanged, compared to its average volume of 18,660,322. The company has a market cap of $62.38 billion, a price-to-earnings ratio of 18.20, a P/E/G ratio of 1.04 and a beta of 0.58. The firm has a 50 day simple moving average of $44.93 and a 200-day simple moving average of $57.15. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The business’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts forecast that Boston Scientific will post 3.18 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 189,522 shares of company stock valued at $9,157,810 in the last three months. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently made changes to their positions in BSX. BlackRock Inc. bought a new position in shares of Boston Scientific during the second quarter worth about $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific in the second quarter valued at $2,156,233,000. Jupiter Topco LLC bought a new stake in Boston Scientific during the second quarter worth $803,357,000. Bank of America Corp DE acquired a new stake in Boston Scientific in the second quarter valued at $556,026,000. Finally, Legal & General Group Plc bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $431,890,000. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Despite reducing forecasts, several analysts still see upside. UBS maintained a Buy rating with a $57 target, while Needham and BTIG also retained Buy ratings; Bernstein, Baird and UBS targets remain above the current share price. Analyst upgrades and downgrades
• Positive Sentiment: Management continues to express confidence in Boston Scientific’s long-term strategy, while reported revenue of approximately $5.14 billion exceeded consensus expectations. The company also said it is targeting renewed growth after the expected 2027 trough. Boston Scientific long-term investor takeaways
• Neutral Sentiment: Third-quarter adjusted EPS of $0.73 met estimates and revenue increased year over year, but the results were overshadowed by lower margins, soft segment performance and reduced full-year guidance. BSX third-quarter earnings
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to disrupt operations. Management’s fourth-quarter outlook implies declining sales and adjusted EPS of $0.77–$0.79, below market expectations. Boston Scientific cybersecurity impact
• Negative Sentiment: Analyst sentiment has deteriorated: TD Cowen downgraded BSX to Hold with a $46 target, JPMorgan moved to Neutral, and Oppenheimer cut its rating to Market Perform. Zacks also added the shares to its Strong Sell list. TD Cowen rating
• Negative Sentiment: Investors are also concerned about electrophysiology and WATCHMAN weakness, China pricing pressure and expectations for largely flat growth in 2027, all of which could delay the company’s earnings recovery. BSX growth challenges through 2027

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.